Our aim was to evaluate the effects of enalapril/lercanidipine combination on some emerging biomarkers for cardiovascular risk stratification of hypertensive patients , such as lipoprotein ( a ) -LSB- Lp ( a ) -RSB- , soluble advanced glycation end products ( sRAGE ) , soluble CD@ ligand ( sCD@L ) and serum myeloperoxidase ( MPO ) .